EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Friday, March 29th 2019 at 7:01pm UTC TORONTO–(BUSINESS WIRE)– Northern Biologics Inc., a company focused on developing first-in-class immuno-oncology products, today announced the presentation of initial results from the Phase I trial of their lead antibody, MSC-1, at the American Association for Cancer Research meeting in Atlanta, Georgia. Session Title: …
Plus »Groupe Santé Devonian émet des titres en règlement des intérêts dûs aux détenteurs de débentures et octroie des options
Friday, March 29th 2019 at 6:00pm UTC CE COMMUNIQUÉ NE DOIT PAS ÊTRE DIFFUSÉ, PUBLIÉ OU DISTRIBUÉ, EN TOUT OU EN PARTIE, AUX ÉTATS-UNIS QUÉBEC–(BUSINESS WIRE)– Groupe Santé Devonian Inc. (la « Société » ou « Devonian ») (Bourse de croissance TSX : GSD), une société biopharmaceutique au stade clinique, annonce l’émission des titres suivants en …
Plus »Devonian Health Group Issues Securities in Interest Settlement Due to Debenture Holders and Grants Options
Friday, March 29th 2019 at 6:00pm UTC NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. QUEBEC–(BUSINESS WIRE)– Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV:GSD), a clinical stage biopharmaceutical corporation, today announces the issuance of the following securities in consideration of interest …
Plus »Acerus Pharmaceuticals Corporation Announces Closing of Private Placement
Friday, March 29th 2019 at 11:00am UTC NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO–(BUSINESS WIRE)– Acerus Pharmaceuticals Corporation (the “Company”) (TSX:ASP) is pleased to announce that it has …
Plus »Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346
Friday, March 29th 2019 at 11:00am UTC TORONTO–(BUSINESS WIRE)– Antibe Therapeutics Inc. (« Antibe » or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that its Phase 2B dose-ranging, efficacy study for ATB-346 has formally commenced. Enrollment is open, clinical sites have …
Plus »Extending IT Authentication Tools to the Door: Unifying Physical and Digital Identity in the Workplace
Thursday, March 28th 2019 at 1:00pm UTC TORONTO–(BUSINESS WIRE)– BioConnect continues to be a leader in the physical security space and seeks to unify the world of physical and digital security through secure identity-based solutions. Physical security technology has been slow to keep pace with the digital innovation that is …
Plus »UN NOUVEAU RAPPORT SUR LA BIOÉCONOMIE CANADIENNE RÉVÈLE LE POTENTIEL VERT DE MARCHÉS DE TALENTS ÉMERGENTS
Thursday, March 28th 2019 at 12:27pm UTC OTTAWA, Ontario–(BUSINESS WIRE)– Un rapport national sur le marché du travail publié aujourd’hui présente les tendances du secteur de la bioéconomie. De plus en plus varié, celui-ci englobe désormais le cannabis médicinal, la santé numérique et l’intelligence artificielle ainsi que le développement durable. …
Plus »New Canadian Bio-Economy Report Indicates Green Potential of Emerging Talent Markets
Thursday, March 28th 2019 at 12:26pm UTC OTTAWA, Ontario–(BUSINESS WIRE)– A national labour market report released today highlights labour trends in the expandingly diverse biotech sector that now also includes medical cannabis, digital health and artificial intelligence, and sustainable development. “Green crossovers – Emerging horizons in Canada’s bio-economy,” examines the …
Plus »New Ventures BC and BioTalent Canada Announce Partnership to Maximize BC Biotech’s Access to Top Talent
Tuesday, March 26th 2019 at 3:19pm UTC VANCOUVER, British Columbia–(BUSINESS WIRE)– New Ventures BC and BioTalent Canada today announced a new partnership to assist BC biotech companies to access funding to hire post-secondary students for business and tech roles to help drive their objectives forward. The Innovate BC Innovator Skills …
Plus »Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer
Tuesday, March 26th 2019 at 11:05am UTC DARTMOUTH, Nova Scotia–(BUSINESS WIRE)– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first …
Plus »
